AG
LRMR icon

Artal Group’s Larimar Therapeutics LRMR Stock Holding History

Artal Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-58,333
Closed -$1.92M – 113
2019
Q1 		$1.92M Hold
58,333
– – 0.08% 96
2018
Q4 		$3.46M Sell
58,333
-8,334
-13% -$823K 0.13% 78
2018
Q3 		$9.35M Sell
66,667
-33,333
-33% -$4.05M 0.24% 57
2018
Q2 		$12.3M Hold
100,000
– – 0.26% 41
2018
Q1 		$8.94M Buy
100,000
+16,667
+20% +$1.41M 0.11% 50
2017
Q4 		$4.62M Hold
83,333
– – 0.07% 74
2017
Q3 		$3.52M Hold
83,333
– – 0.06% 76
2017
Q2 		$3.51M Hold
83,333
– – 0.06% 76
2017
Q1 		$4.66M Buy
83,333
+41,666
+100% +$2.07M 0.1% 62
2016
Q4 		$1.59M Buy
+41,667
New +$1.69M 0.04% 82

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Artal Group's LRMR Position: Q2 2019 in Review

Artal Group sold out of Larimar Therapeutics (LRMR) in Q2 2019, closing a stake of 58,333 shares — an estimated $1.92M sold.

Artal Group first reported a position in LRMR in Q4 2016 and held it in 10 quarters. The position peaked at $12.3M in Q2 2018. 71 funds tracked by Wall St. Rank hold LRMR as of Q2 2019.

  • Artal Group reported no remaining Larimar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Artal Group sold 58,333 Larimar Therapeutics shares in Q2 2019, an estimated $1.92M.
  • Artal Group first reported a position in Larimar Therapeutics in Q4 2016 and held it in 10 quarters.
  • Artal Group's Larimar Therapeutics position peaked at $12.3M in Q2 2018.
  • 71 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2019.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.